



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 7, 2019

Gil M. Labrucherie  
Senior Vice President and Chief Financial Officer  
Nektar Therapeutics  
455 Mission Bay Boulevard South  
San Francisco, CA 94158

**Re: Nektar Therapeutics**  
**Form 10-K for the Fiscal Year Ended December 31, 2017**  
**Filed March 1, 2018**  
**File No. 000-24006**

Dear Mr. Labrucherie:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance